N-Acetyl Cysteine (NAC) per Helicobacter pylori Infection

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

In sintesi

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

Key Study Findings

In Vitro

Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity.

Dose: MIC 11 μg/mL vs: None Outcome: anti-Helicobacter pylori activity Effetto: None None

Popolazione: None

Other

Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter …

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: Published erratum (correction notice)

Review

Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Other

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.

Dose: None vs: None Outcome: Cancer outcomes Effetto: None None

Popolazione: Cancer patients

In Vitro

Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production.

Dose: None vs: None Outcome: choline levels/cognition Effetto: None None

Popolazione: Mice

Other

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human …

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Key Statistics

Studi

250

Partecipanti

↑

Positive

Grado

Referenced Papers

Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity. Other

mLife 2026

Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis. Review

Biochimica et biophysica … 2025 1 citazioni

Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection". Other

Oxidative medicine and … 2025

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy. Other

Pharmaceutics 2024 8 citazioni

Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production. Other

Frontiers in cellular … 2023 7 citazioni

CagA+ Helicobacter pylori, Not CagA- Helicobacter pylori, Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation. Other

Frontiers in cardiovascular … 2022 27 citazioni

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human Gastric Epithelial Cells. Other

Nutrients 2022 11 citazioni

Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine Against Biofilms of Five Common Pathogens. Other

Microbial drug resistance … 2020 34 citazioni

Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized … Other

Therapeutic advances in … 2020 7 citazioni

Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori. Other

Molecules (Basel, Switzerland) 2020

Multidrug resistance in Helicobacter pylori: current state and future directions. Review

Expert review of … 2019 85 citazioni

N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Meta-Analysis

The Cochrane database … 2019 21 citazioni

N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection. Other

Oxidative medicine and … 2018 93 citazioni

The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis. Meta-Analysis

Helicobacter 2018 18 citazioni

N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection. Other

Journal of microbiology … 2017 16 citazioni

Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. Other

Cell host & … 2016 101 citazioni

Helicobacter pylori Activates IL-6-STAT3 Signaling in Human Gastric Cancer Cells: Potential Roles for Reactive Oxygen Species. Other

Helicobacter 2016 60 citazioni

Supplementation with Angelica keiskei inhibits expression of inflammatory mediators in the gastric mucosa of Helicobacter pylori-infected mice. Other

Nutrition research (New … 2016 25 citazioni

Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3β in human gastric cancer cells. Other

Molecular carcinogenesis 2016 18 citazioni

Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. RCT

Gut and liver 2016 17 citazioni

Helicobacter pylori induces IL-1β and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling … Other

Pathogens and disease 2015 64 citazioni

Current Helicobacter pylori treatment in 2014. Review

World journal of … 2015 21 citazioni

Oxidative DNA Damage Response in Helicobacter pylori-Infected Mongolian Gerbils. Other

Journal of cancer … 2013 10 citazioni

Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Review

Alimentary pharmacology & … 2012 104 citazioni

Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Other

Clinical and experimental … 2012 1 citazioni

The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. Other

Journal of clinical … 2011 34 citazioni

Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. RCT

Clinical gastroenterology and … 2010 103 citazioni

Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. Other

Pharmaceutical biology 2010 16 citazioni

Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. Other

Probiotics and antimicrobial … 2010 9 citazioni

N-acetylcysteine: multiple clinical applications. Review

American family physician 2009

A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? CCT

Helicobacter 2007 130 citazioni

Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. RCT

World journal of … 2007 77 citazioni

Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. Other

Journal of agricultural … 2007 44 citazioni

Thiol-oxidant monochloramine mobilizes intracellular Ca2+ in parietal cells of rabbit gastric glands. Other

American journal of … 2007 11 citazioni

N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Other

Digestive diseases and … 2004 53 citazioni

Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection. Other

Digestive diseases and … 2004 4 citazioni

Role of NF-kappaB and AP-1 on Helicobater pylori-induced IL-8 expression in AGS cells. Other

Digestive diseases and … 2003 69 citazioni

Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells. Other

Annals of the … 2002 30 citazioni

Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. Other

Journal of environmental … 2002

The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic … Other

Pharmacological research 2001 25 citazioni

[Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine]. RCT

Schweizerische medizinische Wochenschrift 1994 22 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:: 600-1,200 mg/day in divided doses
hpyloriadjunct:: 600 mg twice daily alongside standard triple therapy
antioxidantsupport:: 600-900 mg/day

Limite massimo: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Dosaggi studiati nella ricerca

Dosaggio	Durata	Effetto	N
MIC 11 μg/mL	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Negative	--
None	--	Positive	--

Momento migliore per l'assunzione: With or without food; divide doses throughout the day

Safety & Side Effects

Effetti collaterali segnalati

⚠ Nausea and vomiting (most common, especially at higher doses)
⚠ Diarrhea
⚠ Unpleasant sulfur taste/odor
⚠ Headache

Interazioni note

● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
● Activated charcoal (may reduce NAC absorption)
● Anticoagulants (NAC may have mild antiplatelet effects)
● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)

Livello di assunzione massimo tollerabile: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does N-Acetyl Cysteine (NAC) help with Helicobacter pylori Infection?

Based on 3 studies with 250 participants, there is limited but promising evidence that N-Acetyl Cysteine (NAC) may support Helicobacter pylori Infection management. Our evidence grade is C (Some Evidence).

How much N-Acetyl Cysteine (NAC) should I take for Helicobacter pylori Infection?

Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of N-Acetyl Cysteine (NAC)?

Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for N-Acetyl Cysteine (NAC) and Helicobacter pylori Infection?

We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 250 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Helicobacter pylori Infection

Lactobacillus gasseri B

N-Acetyl Cysteine (NAC) per altre condizioni

Inflammatory Bowel Disease (IBD) — General D

Verdetto rapido

NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.

Evidence Strength52%

Moderate confidence

Analisi degli studi

RCT (4)Meta (2)Other (0)

Confronta le alternative

Scoprite come si confrontano altri ingredienti per questa condizione.

Visualizza tutti gli ingredienti per Helicobacter pylori Infection

Approfondimenti

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.